Hjem › T-celle-lymfom › Oklahoma
T-celle-lymfom kliniske forsøg i Oklahoma
3 studier for T-celle-lymfom søger deltagere på steder i Oklahoma.
Officiel studietekst (engelsk)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04803201Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- University of Oklahoma Health Sciences Center, Oklahoma City
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 14. sep. 2026 · NCT06724237Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Saint Francis Children's Hospital, Tulsa
RekruttererFase 2
Alder 1 til 18 · Alle køn · Opdateret 10. aug. 2026 · NCT06390319Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.